Cross-sectional associations of objectively-measured sleep characteristics with obesity and type 2 diabetes in the PREDIMED-Plus trial.

Nuria Rosique-Esteban[*1,2], Christopher Papandreou[*1,2], Dora Romaguera[2,3], Julia Warnberg[2,4], Dolores Corella[2,5], Miguel Ángel Martínez-González[2,6,7], Andrés Díaz-López[1,2], Ramon Estruch[2,8], Jesus Vioque[9,10], Fernando Arós[2,11], Antonio Garcia-Rios[2,12], Aurora Bueno-Cavanillas[13,10], Josep Vidal[14], Luís Serra-Majem[2,15], Abdurrahman Adlbi Sibai[16,10], Francisco J. Tinahones[2,17], J. Alfredo Martínez[2,18], José M. Ordovás[19,20], Josep A. Tur[2,21], Macarena Torrego Ellacuría[22], Albert Sanllorente[2,23], Xavier Pintó[2,24], Pilar Buil-Cosiales[2,6,25], Rebeca Fernández-Carrion[2,5], Olga Castañer[2,23], Mónica Bulló[2,1], Miguel Ruiz-Canela[2,6], Manoli García de la Hera[9,10], Napoleon Pérez-Farinós[2,4], F. Javier Barón-López[2,4], Antoni Colom[2,3], Itziar Abete[2,18], Emilio Ros[2,8] and Jordi Salas-Salvadó[‡1,2].

[1]Rovira i Virgili University. Department of Biochemistry and Biotechnology. Human Nutrition Unit, IISPV, Hospital Universitari Sant Joan de Reus, Spain.

[2]CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.

[3]Instituto de Investigación Sanitaria de Illes Balears (IdISBa), University Hospital of Son Espases, Palma de Mallorca, Spain.

[4]University of Malaga-Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.

[5]Department of Preventive Medicine, University of Valencia, Valencia, Spain.

[6]University of Navarra-Navarra Institute for Health Research (DISNA), Department of Preventive Medicine and Public Health, Pamplona, Spain.

[7]Harvard TH Chan School of Public Health, Department of Nutrition, Boston, USA.

[8]Department of Internal Medicine, Hospital Clínic, IDIBAPS August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.

[9]Nutritional Epidemiology Unit, University of Miguel Hernández, ISABIAL-FISABIO, Alicante, Spain.

[10]CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

[11]Department of Cardiology, University Hospital Araba, Vitoria, Spain.

[12]Lipids and Atherosclerosis Unit, Department of Internal Medicine, Reina Sofia University Hospital, IMIBIC, University of Córdoba, Córdoba, Spain.

[13]Departament of Preventive Medicine and Public Health, University of Granada, Spain.

[14]Endocrinology and Nutrition Department. Hospital Clínic Barcelona, Spain. Institut Investigacions Biomediques August Pi Sunyer, Barcelona, Spain. CIBER en Diabetes y Enfermedades Metabólicas (CIBERDEM), Spain.

[15]Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

[16]Preventive Medicine and Public Health Department, University of Leon, Spain.

[17]Department of Endocrinology and Nutrition, Virgen de la Victoria Hospital, Malaga University, Malaga, Spain.

[18]Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain.

[19]Madrid Institute for Advanced Studies (IMDEA) Food Institute, Madrid, Spain.

[20]JM-USDA-Human Nutrition Research Center on Aging at Tufts University, Boston, USA.

[21]Research Group on Community Nutrition and Oxidative Stress, University of the Balearic Islands, Palma de Mallorca, Spain.

[22]Servicio de Endocrinología y Nutrición. Instituto de Investigación Sanitaria San Carlos (Idissc). Madrid, Spain.

[23]Cardiovascular Risk and Nutrition (Regicor Study Group), Hospital del Mar Research Institute (IMIM), Barcelona, Spain.

[24]Lipid Unit, Department of Internal Medicine, Bellvitge Biomedical Research Institute (IDIBELL)-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

[25]Atención Primaria. Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain.

*These authors contributed equally to this work.

Address where the work was conducted: Human Nutrition Unit. Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, C/ Sant Llorenç, 21, 43201 Reus (Spain).

‡**Corresponding author:** Jordi Salas-Salvadó, MD, PhD. Human Nutrition Unit. Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, C/ Sant Llorenç, 21, 43201 Reus (Spain). Telephone number: +34 977759312; Fax number: +34 977759322. E-mail address: jordi.salas@urv.cat

ABSTRACT

Study objectives: To examine independent and combined associations of sleep duration and sleep variability with body composition, obesity and type 2 diabetes (T2D) in elders at high cardiovascular risk.

Methods: Cross-sectional analysis of 1986 community-dwelling elders with overweight/obesity and metabolic syndrome from PREDIMED-Plus trial. Associations of accelerometry-derived sleep duration and sleep variability with BMI, waist circumference (WC) and body composition were assessed fitting multivariable-adjusted linear regression models. Prevalence ratios (PR) and 95% confidence intervals (CI) for obesity and T2D were obtained using multivariable-adjusted Cox regression with constant time. "Bad sleepers" (age-specific non-recommended sleep duration plus sleep variability above the median) and "good sleepers" (age-specific recommended sleep duration plus sleep variability below the median) were characterized by combining sleep duration and sleep variability, and their associations with these outcomes were examined.

Results: One h/night increment in sleep duration was inversely associated with BMI [β-0.38kg/m^2 (95%CI -0.54, -0.23)], WC [β-0.86cm (95%CI -1.25, -0.47)], obesity [PR0.96 (95%CI 0.93, 0.98)], T2D [PR0.93 (95%CI 0.88, 0.98)] and other DXA-derived adiposity-related measurements (android fat and trunk fat, all P<.05). Each 1h-increment in sleep variability was positively associated with T2D [PR1.14 (95%CI 1.01, 1.28)]. Compared with "good sleepers", "bad sleepers" were positively associated with obesity [PR1.12 (95%CI 1.01, 1.24)] and T2D [PR1.62 (95%CI 1.28, 2.06)].

Conclusions: This study revealed cross-sectional associations of sleep duration with adiposity parameters and obesity. Sleep duration and sleep variability were associated with T2D. Considering simultaneously sleep duration and sleep variability could have additional value, particularly for T2D, as they may act synergistically.

Keywords: sleep duration, night-to-nigh sleep variability, accelerometry, adiposity, obesity, type 2 diabetes, body composition.

Trial registration number: ISRCTN89898870 (http://www.isrctn.com/ISRCTN89898870)

STATEMENT OF SIGNIFICANCE

The present work, conducted in elders with obesity and metabolic syndrome within the PREDIMED-Plus trial, agrees on previous literature in that nocturnal sleep duration is relevant for both adiposity, obesity and type 2 diabetes. Furthermore, it adds on novel knowledge about relevant associations between night-to-night sleep variability and type 2 diabetes in this age group. Future research should prospectively confirm these observations in this and other population groups.

INTRODUCTION

The increasing prevalence rates of obesity and related metabolic disorders parallel an epidemic of sleep disturbances, which results from the curtailment in habitual sleep duration and poor sleep quality [1]. Several lines of evidence from experimental [2,3] and epidemiological studies in middle-aged [4–9] and older adults [9–11] have consistently revealed positive associations between short sleep duration and body mass index (BMI) or other adiposity measurements —including waist circumference (WC) and total fat mass [6,8–11]—as well as with poor glucose control and type 2 diabetes (T2D) risk [5,7]. While most of this evidence is of cross-sectional nature [5–9,11,12] and based on self-report sleep measures [7–10,13], those few studies assessing these associations prospectively [6,10,13] or using accelerometry [6,11] have shown similar results.

Besides sleep duration, disruptions of sleep-wake patterns have also been linked to obesity and metabolic dysregulation [14]. In fact, in experimental studies, sleep-wake cycle disturbances have proven to induce obesity-driving effects, such as increases in the preference for calorie-dense foods, reductions in energy expenditure and adverse effects on appetite-related hormones [15]. High night-to-night variability in sleep duration reflect such disruptions in sleep-wake patterns and a number of epidemiological studies among young and older adults have reported positive associations between high sleep variability and adiposity parameters [11,16,17]. Furthermore, poor glucose control has been related to high sleep variability in children [18]. In spite of this limited

evidence, no study has yet evaluated the association between sleep variability and T2D in other age groups. Moreover, the associations of sleep duration in relation to adiposity parameters, obesity and T2D remain unexplored in elderly adults with overweight/obesity and metabolic syndrome, a population susceptible to metabolic and age-related sleep disturbances [19]. From a public health perspective, these associations are of great importance, since identification of sleep characteristics that are strongly related to an increase risk of obesity and T2D could facilitate the development of public health advice specifically targeted at the improvement of sleep habits and subsequent management of the aforementioned conditions in this vulnerable group.

Taking the above into account, the present study aimed to cross-sectionally examine independent associations of objectively measured sleep duration and sleep variability with adiposity parameters, obesity and T2D in an elderly Mediterranean population at high cardiovascular risk. Since sleep duration and sleep variability may not only affect metabolic health in an independent manner, but also may act synergistically, joint associations of sleep duration and sleep variability with the aforementioned study outcomes were also assessed.

SUBJECTS AND METHODS

Study design and population

This is a cross-sectional analysis of baseline data from the PREDIMED-Plus trial, a 6-year lifestyle intervention study aiming at evaluating a lifestyle strategy for the prevention of cardiovascular morbimortality on 6874 senior adults (the protocol is available at http://predimedplus.com/ and the trial was registered at the International Standard Randomized Controlled Trial http://www.isrctn.com/ISRCTN89898870).

Eligible participants were community-dwelling adults (aged 55-75 in men; 60-75 in women) with body mass index (BMI) ≥27 and <40 kg/m^2, and meeting ≥3 metabolic syndrome individual components [20]. Study participants involved in the present analyses were included as detailed in the flow-chart (**Supplemental Figure S1)**. Briefly, out of the 6874 participants

recruited from a total of 23 centers of the PREDIMED-Plus trial, accelerometry data at baseline was available in a subsample of participants (n=1993) to whom accelerometry was randomly offered. Participants with incomplete accelerometry-derived sleep data were excluded (n=7), resulting in an effective sample size of 1986. Additionally, total dual-energy X-ray absorptiometry (DXA) scans were performed in 7 out of the 23 recruiting centers. Therefore, only a subsample of the participants with accelerometry-derived sleep data also underwent DXA scans, and the sample size for those analysis involving DXA-derived body composition parameters was 649. Data for DXA-derived visceral adipose tissue (VAT) mass was available in 4 of the 7 recruiting centers with access to CoreScan software, thus, the analyses involving VAT in the present study included n=288 participants. Study protocol and procedures were approved following the ethical standards of the Declaration of Helsinki by the Institutional Review Boards of the recruiting centers. All participants provided written informed consent.

Sleep and physical activity assessment by accelerometry

A wrist-worn triaxial accelerometer (GENEActiv, ActivInsights Ltd, Kimbolton, United Kingdom) was used to monitor daily activities and sleep patterns. Participants were asked to wear the accelerometer on their non-dominant wrist nonstop during the evaluation, which was established for 8 consecutive 24-hour days. However, the total amount of monitored days varied according to the day of the clinical visit and the day the monitor was returned. The data used for the analysis in this study was extracted between the first and the last sleep period and included only if the monitor had been worn for ≥16h per day, and have a minimum of two valid days. The accelerometer data was recorded at 40 Hz with a ±8g dynamic range, and acceleration data was expressed relative to gravity (*g*) units (1 *g* = 9.81 m/second²). Raw data files were managed on servers at the University of Málaga and processed with R-package (R Core Team, Vienna, Austria) using the open-source R-package GGIR, version 1.2-5 (cran.r-project.org/web/packages/GGIR/index.html). This open source code has been validated in relation to self-calibrated functions [21]. The method of sleep detection has been previously validated in individuals with at least one valid night and it has been published elsewhere [22].

Briefly, by visualizing the arm angle, night sleep and daytime napping were characterized as a period marked by a low frequency of changes in arm angle. After the detection of the onset of the night, the average nocturnal sleep duration, and intra-individual between-night standard deviation of the sleep duration was calculated. Sleep duration was defined as the time between sleep onset to wake, excluding the time spent awake in between these two time-points. To use as a covariate, the time spent in moderate to vigorous physical activity (MVPA) in bouts of 10 minutes or more was calculated as described previously [23] and further categorized according to compliance of the WHO recommendations for MVPA set in ≥150 min/week [24].

Adiposity parameters and glucose-related indices

Weight (kg) divided by height (meters) squared was used to calculate BMI. WC (cm) was measured with anthropometric tape following the PREDIMED-Plus operations protocol. Obesity was defined as BMI ≥30 kg/m^2. DXA scans (DXA, Lunar iDXA and DXA Lunar Prodigy Primo, GEHealthcare, United Kingdom) were performed by trained radiology technicians to ascertain body composition. For the present study, total fat, android and gynoid fat, VAT, trunk fat and lean mass (all expressed in kg) were included. VAT (kg) was obtained using the GE CoreScan software. Android fat was divided by gynoid fat to calculate android-to-gynoid ratio.

Fasting plasma glucose (mg/dl) and glycated hemoglobin (HbA1c, %) were determined using standard enzymatic methods. T2D was defined as previous clinical diagnosis of diabetes, or HbA1c ≥6.5% or use of antidiabetic medication at baseline or fasting plasma glucose >126 mg/dl in both the screening visit and baseline visit.

Other covariates

Self-reported age, sex, education, marital and employment status, smoking habits, depression, sleep apnea and use of sedatives were recorded based on structured interviews. Participants completed a 17-item questionnaire to evaluate the adherence to an energy-restricted Mediterranean diet (MedDiet). Total daily intake (g/day) of alcohol, carbohydrate, fat, protein and sugar were calculated using a semi-quantitative food frequency questionnaire [25]. Blood

pressure was measured in triplicate with a semiautomatic oscillometer (Omron HEM-705CP, Netherlands) and high blood pressure was defined as systolic and/or diastolic blood pressure ≥130/85 mmHg or using antihypertensive drugs.

Statistics

Baseline characteristics were examined for the total study population and across five categories of night sleep duration (<6h, 6-<7h, 7-<8h, 8-<9h and ≥9/h). One-way ANOVA and Chi-square tests were used, as appropriate, to examine between-categories differences.

Linear regression models were fitted to examine the associations of 1-hour/day increment in sleep duration and sleep variability with BMI, WC, DXA-derived body composition measurements, fasting plasma glucose, and HbA1c. Since obesity and T2D were highly prevalent (all of them >10%), Cox regression models with constant time of follow-up set at *t*=1 (given the cross-sectional design) and robust variance estimates rather than logistic regression [26,27] were employed to assess prevalence ratios (PR) for obesity and T2D. A number of models were examined. For all outcomes, model 1 was adjusted for sex and age (continuous). Model 2 was further adjusted for smoking habits (current smoker, past smoker, never smoked), education level (primary education, secondary education, academic/graduate), marital status (single/divorced, married and widower) and employment status (working, non-working, retired), sedative medication (yes/no), current or previous depression (yes/no), adherence to an energy-restricted MedDiet (score from 0 to 17-items, continuous), alcohol consumption (g/day, continuous and adding a quadratic term), compliance to MVPA recommendations set in ≥150 min/week (yes/no), daytime napping (min/day) and recruiting center. Beside these covariates, model 2 in each outcome was specifically adjusted for factors that may affect these associations. Model 2 for BMI, WC and body composition parameters was further adjusted for T2D (yes/no). Model 2 for fasting plasma glucose was further adjusted for WC (continuous). Model 2 for HbA1c was further adjusted for WC (continuous) and anti-diabetic medication (yes/no). Model

2 for obesity was further adjusted for T2D and high blood pressure (yes/no). Model 2 for T2D was further adjusted for obesity and high blood pressure (yes/no). For all outcomes, model 3 included variables in model 2 plus current or previous sleep apnea (yes/no). A fourth model was fitted by including variables from model 3 plus sleep variability in case of evaluating sleep duration as exposure, or sleep duration in case of evaluating sleep variability as exposure, in order to account for possible influence of one another in their associations with the study outcomes. We used multiple imputation method using the Stata 'MI' module (the number of imputation was set to 20) to replace the missing values of HbA1c in 178 participants. Time spent in daytime napping was log transformed to approximate normality.

Joint analyses relied on the combination of categories of sleep duration with categories of sleep variability, in relation to all study outcomes. Based on these categories, a total of six joint categories were created: 1) category 1 ("good sleepers") included those participants following their age-specific recommended sleep duration (7-9 h/night sleep for individuals with <65y and 7-8h/night for individuals with ≥65y) plus low sleep variability (< median sleep SD) (n=400), 2) category 2 included participants with sleep duration that may be appropriate according to their age, plus low sleep variability (n=489); 3) category 3 included participants with non-recommended sleep duration plus low sleep variability (n=96); 4) category 4 included participants following their age-specific recommended sleep duration plus high sleep variability (n=385); 5) category 5 included participants with sleep duration that may be appropriate according to their age, plus high variability (n= 469); and 6) category 6 ("bad sleepers") for participants with non-recommended sleep duration (<6h/night sleep for individuals with <65y and <5h/night for individuals with ≥65y or ≥9h/night) plus high sleep variability (≥ median sleep SD) (n=147).

A more detailed description of how categories and groups were built is provided in **Supplemental Information 2**. For joint analyses, all categories were compared with category 1 "good sleepers" (reference) against the study outcomes. In order to address whether the magnitude of association revealed by the joint analyses on obesity and T2D was different to that

from sleep duration and sleep variability separately, we tested fully-adjusted Cox regression models using categories of short sleep (<6h/nocturnal sleep duration) *vs*. recommended sleep [≥7-9h/nocturnal sleep duration (reference)], as well as for categories of high sleep variability *vs*. low sleep variability (reference).

To account for multiple-testing, Benjamini-Hochberg false discovery rate (FDR) procedure [28] was applied and statistical significance was defined as FDR <0.05. Effect modification by sex, age (<65y, ≥65 y) and T2D on the associations between sleep variables (sleep duration and sleep variability) on each study outcome were tested using the likelihood ratio test between the fully adjusted model and the same model adding the interaction product-term.

The robustness of the findings was tested by performing a number of sensitivity analyses: a) excluding those participants sleeping ≥9/h per night (n=38), and b) excluding those participants with previous/current comorbidities, such as neurodegenerative disorders (n=3), previous/current depression (n=420), previous non-atherosclerotic cardiovascular disease (thrombosis, n=30 and cardiopathy, n= 43), previous nephropathy (n=123) and previous cancer (n=143), and c) excluding those participants with <5 nights of valid accelerometry-derived sleep data (n=127).

Values are presented as means and 95% confidence intervals (CI), unless otherwise indicated. All analyses were cross-sectional and were conducted using Stata (14.0, StataCorp, Tx, USA) and statistical significance was set as <.05.

RESULTS

Baseline characteristics for the entire population and by categories of nocturnal sleep duration are displayed in **Table 1**, and summarized according to categories of sleep variability in **Table S1.** The mean age of participants was 65.0y and the mean nocturnal sleep duration and sleep variability were 6.9±1.1h and 0.89±0.4h, respectively. The mean BMI in the population was 32.6±3.4 kg/m^2. According to categories of sleep duration, those participants in the categories of shorter nocturnal sleep duration (<6h and 6-<7h) were more likely to be young, men and current

smokers. They were also more likely to have central obesity indices, consume more alcohol, have higher fat intake and adhere less to an energy-restricted MedDiet, along with having higher education and being currently employed (**Table 1**). Participants involved in the analysis concerning DXA measures (with or without VAT data available) did not differ from those with accelerometry-derived sleep data only, nor from the rest of the participants enrolled in the PREDIMED-Plus trial in terms of age, sex, BMI, and prevalence of obesity and T2D (P>.05 for all comparisons). No significant differences in these characteristics were also observed between participants with accelerometry data and the rest of the participants enrolled in the PREDIMED-Plus trial.

In multivariable-regression analyses, 1h/night increment in sleep duration was inversely and significantly associated with BMI, WC, some of the DXA-derived adiposity measurements (android fat and trunk fat) (**Table 2** and **Table S2**). Each 1h increment in sleep variability was not significantly associated with any of the continuous outcomes (**Table 3** and **Table S2**). Concerning HbA1c, these associations remained non-significant after excluding those participants using anti-diabetic medication (n=479) (data not shown). **Figure 1** shows the multivariable-PR (95%CI) of obesity and T2D per each 1h/night increment in sleep duration and sleep variability, in fully adjusted models. Associations are fully displayed in **Table S3**. A 1h/night increment of sleep duration was associated with a 4% and 7% lower prevalence of obesity and T2D, respectively. Additionally, incrementing 1h sleep variability was associated with significantly higher T2D prevalence, even after adjusting for sleep duration. No significant association was found between sleep variability and obesity prevalence. The associations of sleep duration and sleep variability with obesity and T2D remained unchanged in magnitude and strength when analyses where conducted removing the covariates T2D, obesity and high blood pressure from the fully adjusted model.

Being characterized as "bad sleeper" was positively associated with BMI, fasting plasma glucose and HbA1c (**Table 4**), as well as with higher obesity and T2D prevalence (**Figure 2a** and **Figure 2b,** respectively) as compared to "good sleepers". Participants with non-

recommended sleep duration plus low sleep variability (Category 3) were also significantly associated with high obesity prevalence (**Figure 2a**). Participants with sleep duration that may be appropriate according to their age-specific plus high variability (Category 5) were positively associated with T2D (**Figure 2b**). No significant associations were found in relation to WC and DXA-derived parameters (**Table 4**). Participants in the category of short sleep duration had significantly higher obesity and T2D prevalence than those in the category of longer sleep duration [PR 1.15 (1.07, 1.24) *P*<.001 and PR 1.30 (1.09, 1.55) *P*=.004, respectively]. Similarly, participants in the category of high sleep variability had higher T2D prevalence [PR 1.24 (1.10, 1.39) *P*=.001], but not obesity prevalence [PR 1.03 (0.98, 1.08) *P*=.244], as compared with those in the category of low sleep variability.

No significant interactions with sex, age or T2D were found (*P*>.05 for all interactions). Results from sensitivity analysis on adiposity parameters and T2D were consistent with those of the primary analysis in relation to sleep duration and variability after excluding those participants sleeping ≥9h/night (n=38) (**Table S4**), or participants with <5 nights of valid accelerometry data (n=127) (**Table S5**). Results were also similar when removing those participants with previous/current history of neurodegenerative disorders, depression, non-atherosclerotic cardiovascular disease, nephropathy or cancer (data not shown).

DISCUSSION

The main findings of the present study suggest that one hourly increase in nocturnal sleep duration was inversely associated with adiposity-related anthropometric and DXA-derived body composition parameters, as well as with a 4% and 7% lower prevalence of obesity and T2D, respectively. Contrary, each hourly increase in sleep variability was directly associated with a 14% higher T2D prevalence. When considering their combined effects, “bad sleepers” were positively associated with BMI, fasting plasma glucose, HbA1c, and with a 12% and 62% higher prevalence of obesity and T2D prevalence, respectively.

A number of previous studies have observed inverse associations between nocturnal sleep duration and adiposity-related parameters using both self-reported [8,10,12,29–32] and accelerometry-derived sleep data [11]. For instance, two large population cohorts [NHANES [8] and KNHANES [12,29]] of middle-aged and elder adults, showed that shorter sleep duration was consistently associated with larger BMI, WC, DXA-derived fat mass and obesity.

The inverse association between sleep duration and T2D prevalence observed in the Mediterranean population evaluated in our study is in line with findings from previous cross-sectional [5,7,32] and large prospective studies including middle-aged and older adults in other populations, such as the Nurses' Health Study [13] and EPIC-Norfolk study [33]. Interestingly, the magnitude of association between sleep duration and T2D appeared to be greater than that observed with obesity. This may be partially explained by the high prevalence of obesity in our study population, which could contribute to a decrease in the sensitivity to detect these associations.

Several mechanisms have been suggested to explain the aforementioned observations. Short sleep duration may be accompanied by increased opportunities to eat during the day, as well as by enhanced hedonic perception of highly palatable foods [34]. Accordingly, in our study short sleepers had higher fat intake and lower score for the adherence to a healthy dietary pattern (MedDiet). Short sleep duration may also reduce time devoted to physical activity and its intensity as a result of increased feelings of tiredness, hence perpetuating a positive energy balance and contributing to weight gain and poor glucose control [34]. Admittedly, the cross-sectional design of our study precludes conclusions on the potential causality of these associations.

Current evidence on sleep variability and adiposity parameters in middle-aged and old adults remains scarce and inconsistent. Previous studies showing direct associations between night-to-night sleep variability and obesity in old adults [17] were conducted using self-reported sleep data. However, evidence from other studies using accelerometry-derived sleep variability [11,35], such as that from Ogilvie et al. [11], support our findings in relation to the lack of significant

associations with BMI, WC and total body fat when sleep duration was included in the statistical models. Notably, in our study the magnitude of these associations was similar regardless of including sleep duration as a covariate.

Furthermore, we observed that high sleep variability was independently and positively associated with the prevalence of T2D, suggesting a plausible impact of sleep variability on glucose control in elders with metabolic disturbances. To the best of our knowledge, no previous study has ever evaluated sleep variability in relation to T2D in older populations. Nevertheless, earlier studies evaluating these associations have mostly focused on children [18] and adolescents [36] showing direct associations between high sleep variability or disturbed sleep architecture and alterations in glucose metabolism. Potential mechanisms underlying these observations involve several disruptions at the level of the central nervous system, including impaired cortisol rhythm promoting insulin resistance, as well as in peripheral tissues, such as liver alterations of glucose metabolism or pancreatic beta-cell secretion driven by a pro-inflammatory and pro-oxidative status [37].

As far as we know, this is the first study examining associations between combined sleep duration and sleep variability with obesity and T2D. According to our findings, the magnitude of the associations with T2D increased when sleep duration and sleep variability were combined. We found that participants in the categories of short sleep duration and high sleep variability had 30% and 24% higher T2D prevalence, respectively whereas in joint analysis (category of "bad sleepers" *vs.* "good sleepers") this prevalence raised up to a 62%.

Interestingly, from the results obtained in the joint analyses, it seems that sleep duration, particularly non-recommended sleep duration, has an important contribution on obesity prevalence and the magnitude of association, regardless of low or high sleep variability. In spite of this, the magnitude of association is slightly attenuated when high sleep variability is considered in the joint analyses. Furthermore, the magnitude of the associations with T2D increased when non-recommended sleep duration and high sleep variability were combined, highlighting the importance of considering both sleep characteristics due to their potential

synergistic effects on metabolic health. Nevertheless, these results need to be further confirmed in longitudinal analyses.

A number of limitations in the present study should be acknowledged. First, the cross-sectional design does not allow to make any causal inference of the observed associations, and therefore reverse causation cannot be excluded. Admittedly, the cross-sectional observations derived from the present study are limited in their potential clinically relevance, yet they add on understanding to current knowledge in relation to sleep characteristics, adiposity and T2D. Second, the high prevalence of abdominal obesity (92%) in our study did not allow us to assess its associations with sleep characteristics. In addition, since some of the outcomes in our study were part of the inclusion criteria, the observed associations may have been affected. Third, although the prevalence of sleep apnea was reported in our study, information regarding treatment approaches was not available. Fourth, residual confounding may remain despite adjusting for several potential confounders. Fifth, we acknowledge potential selection bias from including those participants with available data on accelerometry and DXA for the present analyses. Nevertheless, in a series of analyses conducted, we have observed no significant differences between participants with DXA measures (with or without VAT data available) and/or accelerometry data, and the rest of the participants from the PREDIMED-Plus trial in main characteristic variables. Finally, participants were elder Mediterranean adults at high cardiovascular risk, thus results cannot be extrapolated to other study populations. Our study has also several strengths including the use of accelerometry, a reliable method to assess sleep data compared to other subjective tools [38], and the inclusion of DXA-derived body composition parameters in addition to other classical adiposity parameters like BMI or WC.

Conclusions

The findings reported in our study add on new evidence in relation to sleep characteristics, obesity and T2D, which may be particularly relevant for the development of public health strategies in the management of these conditions among elders at high cardiovascular risk. In this population, we found that sleep duration was important for both obesity and T2D

prevalence. Sleep variability, however, was more relevant for T2D. Further studies are required to prospectively confirm our findings and elucidate other possible mechanisms underlying these observations.

ABBREVIATION LIST

T2D, type 2 diabetes

PREDIMED-Plus, Prevención con Dieta Mediterranea-Plus

BMI, body mass index

WC, waist circumference

DXA, dual-energy X-ray absorptiometry

PR, prevalence ratios

CI, confidence intervals

VAT, visceral adipose tissue

MVPA, moderate to vigorous physical activity

WHO, World Health Organization

HbA1c, glycated hemoglobin

MedDiet, Mediterranean diet

FDR, false discovery rate

ACKNOWLEDGEMENTS

The authors especially thank the participants for their enthusiastic collaboration, the PREDIMED-Plus personnel for their excellent assistance, and the personnel of all affiliated primary care centers for their excellent work. CIBERobn is an initiative of Instituto Carlos III, Spain.

DISCLOSURE STATEMENT

Financial Disclosure: none.

Non-financial Disclosure: none.

FINANCIAL STATEMENT

This study was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (three coordinated FIS projects led by J S-S and J Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926), the Especial Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-PLUS grant to J S-S, the European Research Council (Advanced Research Grant 2013-2018; 340918) grant to MÁ M-G, the Recercaixa grant to J S-S (2013ACUP00194), the grant from the Consejería de Salud de la Junta de Andalucía (PI0458/2013; PS0358/2016), the SEMERGEN grant and FEDER funds (CB06/03); PROMETEO excellence grant 17/2017 from the Generalitat Valenciana, Valencia; a grant from International Nut & Dried Fruit Council (FESNAD No. 201302; 2014 –2015), and Grant FEA/SEA 2017 for Primary Care Research. N R-E has been beneficiary of a predoctoral FI AGAUR 2016 Grant from the Catalan Government; Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya. None of the funding sources took part in the design, collection, analysis or interpretation of the data, or in the decision to submit the manuscript for publication. CIBEROBN (Centros de Investigación Biomédica en Red: Obesidad y Nutrición), CIBERESP (Centros de Investigación Biomédica en Red: Epidemiología y Salud Pública) and CIBERDEM (Centros de Investigación Biomédica en Red: Diabetes y Enfermedades Metabólicas asociadas) are initiatives of ISCIII, Madrid, Spain.

REFERENCES

1. Ogilvie RP, Patel SR. The epidemiology of sleep and obesity. *Sleep Heal*. 2017;3(5):383-388. doi:10.1016/j.sleh.2017.07.013.
2. Spiegel K, Leproult R, Cauter E Van. Impact of sleep debt on metabolic and endocrine function. *Lancet*. 1999;354:1435-1439.
3. Spaeth AM, Dinges DF, Goel N. Effects of Experimental Sleep Restriction on Weight Gain, Caloric Intake, and Meal Timing in Healthy Adults. *Sleep*. 2013;36(7):981-990. doi:10.5665/sleep.2792.
4. Vioque J, Torres A, Quiles J. Time spent watching television, sleep duration and obesity in adults living in Valencia, Spain. *Int J Obes*. 2000;24:1683-1688. doi:10.1038/sj.ijo.0801434.
5. Chaput JP, Després JP, Bouchard C, Tremblay A. Association of sleep duration with type 2 diabetes and impaired glucose tolerance. *Diabetologia*. 2007;50(11):2298-2304. doi:10.1007/s00125-007-0786-x.
6. Appelhans BM, Janssen I, Cursio JF, et al. Sleep duration and weight change in midlife women: The SWAN sleep study. *Obesity*. 2013;21(1):77-84. doi:10.1002/oby.20251.
7. Jackson CL, Redline S, Kawachi I, Hu FB. Association between sleep duration and diabetes in black and white adults. *Diabetes Care*. 2013;36(11):3557-3565. doi:10.2337/dc13-0777.
8. Xiao Q, Gu F, Caporaso N, Matthews CE. Relationship between sleep characteristics and measures of body size and composition in a nationally-representative sample. *BMC Obes*. 2016;3(1):48. doi:10.1186/s40608-016-0128-y.
9. Min H, Um YJ, Jang BS, et al. Association between Sleep Duration and Measurable Cardiometabolic Risk Factors in Healthy Korean Women: The Fourth and Fifth Korean National Health and Nutrition Examination Surveys (KNHANES IV and V). *Int J Endocrinol*. 2016;2016. doi:10.1155/2016/3784210.
10. Lopez-Garcia, E; Faubel, R; Leon-Muñoz, L; Zuluaga, MC; Banegas, JR; Rodriguez-Artalejo F. Sleep duration , general and abdominal obesity , and weight change among the older adult population of Spain. *Am J Clin Nutr*. 2008;(6):310-316.
11. Ogilvie RP; Redline, S; Bertoni, AG ; Chen, X ; Ouyang, P ; Szklo, M; Lutsey P. Actigraphy measured sleep indices and adiposity: The multi-ethnic study of atherosclerosis (MESA). *Sleep*. 2016;39(9):1701-1708. doi:10.5665/sleep.6096.

12. Kim K, Shin D, Jung G-U, Lee D, Park SM. Association between sleep duration, fat mass, lean mass and obesity in Korean adults: the fourth and fifth Korea National Health and Nutrition Examination Surveys. *J Sleep Res*. 2017;26(4):453-460. doi:10.1111/jsr.12504.

13. Ayas NT, White DP, Al-Delaimy WK, et al. A Prospective Study of Self-Reported Sleep Duration and Incident Diabetes in Women. *Diabetes Care*. 2003;26(2):2003-2003.

14. Roenneberg T, Allebrandt K V., Merrow M, Vetter C. Social jetlag and obesity. *Curr Biol*. 2012;22(10):939-943. doi:10.1016/j.cub.2012.03.038.

15. Broussard JL, Van Cauter E. Disturbances of sleep and circadian rhythms. *Curr Opin Endocrinol Diabetes Obes*. 2016;23(5):353-359. doi:10.1097/MED.0000000000000276.

16. He F, Bixler EO, Liao J, et al. Habitual sleep variability, mediated by nutrition intake, is associated with abdominal obesity in adolescents. *Sleep Med*. 2015;16(12):1489-1494. doi:10.1016/j.sleep.2015.07.028.

17. Kobayashi D, Takahashi O, Shimbo T, Okubo T, Arioka H, Fukui T. High sleep duration variability is an independent risk factor for weight gain. *Sleep Breath*. 2013;17(1):167-172. doi:10.1007/s11325-012-0665-7.

18. Spruyt K, Molfese DL, Gozal D. Sleep Duration, Sleep Regularity, Body Weight, and Metabolic Homeostasis in School-aged Children. *Pediatrics*. 2011;127(2):e345-e352. doi:10.1542/peds.2010-0497.

19. Zdanys KF, Steffens DC. Sleep Disturbances in the Elderly. *Psychiatr Clin North Am*. 2015;38(4):723-741. doi:10.1016/j.psc.2015.07.010.

20. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention;National heart, lung, and blood institute;American heart association;World heart federation;International. *Circulation*. 2009;120(16):1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644.

21. van Hees VT, Fang Z, Langford J, et al. Autocalibration of accelerometer data for free-living physical activity assessment using local gravity and temperature: an evaluation on four continents. *J Appl Physiol*. 2014;117(7):738-744. doi:10.1152/japplphysiol.00421.2014.

22. Van Hees VT, Sabia S, Anderson KN, et al. A novel, open access method to assess sleep duration using a wrist-worn accelerometer. *PLoS One*. 2015;10(11):1-13.

doi:10.1371/journal.pone.0142533.

23. Menai M, Van Hees VT, Elbaz A, Kivimaki M, Singh-Manoux A, Sabia S. Accelerometer assessed moderate-To-vigorous physical activity and successful ageing: Results from the Whitehall II study. *Sci Rep*. 2017;8(March):1-9. doi:10.1038/srep45772.

24. World Health Organization. Global Recommendations on Physical Activity for Health. http://www.who.int/dietphysicalactivity/factsheet_olderadults/en/. Published 2010. Accessed April 3, 2018.

25. Fernández-Ballart JD, Piñol JL, Zazpe I, et al. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. *Br J Nutr*. 2010;103(12):1808-1816. doi:10.1017/S0007114509993837.

26. Barros, AJD; Hirakata V. Alternatives for logistic regression in cross-sectional studies : an empirical comparison of models that directly estimate the prevalence ratio Alternatives for logistic regression in cross-sectional studies : an empirical comparison of models that direct. *BMC Med*. 2003;13:1-13.

27. Lee J. Odds Ratio or Relative Risk for Cross-Sectional Data? *Int J Epidemiol*. 1994;23(1):201-203. doi:10.1097/gme.0b013e3181967b88.

28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B*. 1995;57(1):289-300.

29. Park SE, Kim HM, Kim DH, Kim J, Cha BS, Kim DJ. The association between sleep duration and general and abdominal obesity in Koreans: Data from the Korean national health and nutrition examination survey, 2001 and 2005. *Obesity*. 2009;17(4):767-771. doi:10.1038/oby.2008.586.

30. Ford ES, Li C, Wheaton AG, Chapman DP, Perry GS, Croft JB. Sleep Duration and Body Mass Index and Waist Circumference among US Adults. *Obesity*. 2014;22(2):598-607. doi:10.1002/oby.20558.Sleep.

31. Chaput JP, Bouchard C, Tremblay A. Change in sleep duration and visceral fat accumulation over 6 years in adults. *Obesity*. 2014;22(5):9-12. doi:10.1002/oby.20701.

32. Potter GDM, Cade JE, Hardie LJ. Longer sleep is associated with lower BMI and favorable metabolic profiles in UK adults: Findings from the National Diet and Nutrition Survey. *PLoS One*. 2017;12(7):1-14. doi:10.1371/journal.pone.0182195.

33. Leng Y, Cappuccio FP, Surtees PG, Luben R, Brayne C, Khaw KT. Daytime napping, sleep duration and increased 8-year risk of type 2 diabetes in a British population. *Nutr Metab Cardiovasc Dis*. 2016;26(11):996-1003. doi:10.1016/j.numecd.2016.06.006.

34. Knutson, KL; van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. *Ann NY Acad Sci*. 2008;(1129):287-304. doi:10.1196/annals.1417.033.

35. Patel SR, Hayes AL, Blackwell T, et al. The association between sleep patterns and obesity in older adults. *Int J Obes*. 2014;38(9):1159-1164. doi:10.1038/ijo.2014.13.

36. Armitage R, Lee J, Bertram H, Hoffmann R. A Preliminary Study of Slow-Wave EEG Activity and Insulin Sensitivity in Adolescents. *Sleep Med*. 2013;14(3):257-260. doi:10.1016/j.sleep.2012.11.012.

37. Briançon-Marjollet A, Weiszenstein M, Henri M, Thomas A, Godin-Ribuot D, Polak J. The impact of sleep disorders on glucose metabolism: endocrine and molecular mechanisms. *Diabetol Metab Syndr*. 2015;7(1):25. doi:10.1186/s13098-015-0018-3.

38. Dashti HS, Zuurbier LA, Jonge E De, et al. Actigraphic sleep fragmentation, efficiency, and duration associate with dietary intake in the Rotterdam Study. *J Sleep Res*. 2016;25(4):404-411. doi:10.1111/jsr.12397.Actigraphic.

Figure 1. Multivariable-Prevalence Ratio (95%CI) for obesity and type 2 diabetes per increment of 1h in nocturnal sleep duration and night-to-night sleep variability.

PR, prevalence ratio; CI, confidence interval. Model adjusted for sex, age (years), marital status (single/divorced, married and widower), employment (working, non-working, retired), education (primary education, secondary education, academic/graduate), smoking habit (current smoker, past smoker, never smoked), high blood pressure (yes/no), sedative treatment (yes/no), sleep apnea (yes/no), depression (yes/no), 17-score energy-restricted Mediterranean diet, alcohol intake (g/day, continuous and adding a quadratic term), compliance to MVPA recommendations set in ≥150 min/week (yes/no), time spent in sustained inactivity bouts ("daytime napping", min/day, log10 transformed) and intervention center. Additionally, the model for obesity was adjusted for type 2 diabetes (yes/no) and high blood pressure (yes/no), whereas the model for type 2 diabetes was adjusted for obesity and high blood pressure (yes/no).

[1]Model additionally adjusted for sleep variability in case of sleep duration or sleep duration in case of sleep variability.

Figure 2. Multivariable-adjusted PR for obesity (a) and type 2 diabetes (b) in joint categories of sleep duration and sleep variability.

PR, prevalence risk; CI, confidence interval; Cat, category. Category 1 ("good sleepers") included those participants following their age-specific recommended sleep duration (7-9 h/night sleep for individuals with <65y and 7-8h/night for individuals with ≥65y) plus low sleep variability (< median sleep SD) (n=400). Category 2 included participants with sleep duration that may be appropriate according to their age-specific plus low sleep variability (n=489). Category 3 included participants with non-recommended sleep duration plus low sleep variability (n=96). Category 4 included participants following their age-specific recommended sleep duration plus high sleep variability (n=385). Category 5 included participants with sleep duration that may be appropriate according to their age-specific plus high variability (n= 469). Category 6 ("bad sleepers") for participants with non-recommended sleep duration (<6h/night sleep for individuals with <65y and <5h/night for individuals with ≥65y or ≥9h/night) plus high sleep variability (≥ median sleep SD) (n=147).

Figure 1


PR (95% CI)
Obesity
Sleep duration
Sleep duration 1
Sleep variability
Sleep variability 1
Type 2 diabetes
Sleep duration
Sleep duration 1
Sleep variability
Sleep variability 1
0.96 (0.93, 0.98)
0.96 (0.93, 0.98)
1.03 (0.97, 1.08)
1.01 (0.95, 1.07)
0.92 (0.87, 0.97)
0.93 (0.88, 0.98)
1.17 (1.04, 1.32)
1.14 (1.01, 1.28)
0.8
1.0
1.2
1.4
1.5

Figure 2



Table 1. Baseline characteristics of the study population from PREDIMED-Plus trial across categories of nocturnal sleep duration.

	Total N=1986	Categories of nocturnal sleep duration (h)					*P*-value
		< 6h n=339	6- <7h n=662	7- <8h n=700	8- <9h n=247	≥9h n=38	
Sleep parameters							
Nocturnal sleep duration, h	6.9 ± 1.1	5.3 ± 0.7	6.5 ± 0.3	7.4 ± 0.3	8.4 ± 0.2	9.3 ± 0.3	<.001
Night sleep variability, h	0.89 ± 0.4	1.0 ± 0.6	0.88 ± 0.4	0.87 ± 0.4	0.83 ± 0.3	0.86 ± 0.3	<.001
Daytime napping duration, min	84.6 ± 41.3	71.5 ± 43.7	73.4 ± 41.3	85.6 ± 45.5	117.5 ± 51.0	166.1 ± 67.2	<.001
Age, y	65.0 ± 4.9	64.1 ± 5.0	64.6 ± 5.2	65.2±4.8	66.3 ± 4.4	67.9 ± 3.7	<.001
Men, n (%)	1058(53)	254(75)	373(56)	326 (46)	93(37)	12(32)	<.001
BMI, kg/m^2	32.6 ± 3.4	33.1 ± 3.4	32.5 ± 3.5	32.4 ± 3.4	32.6 ± 3.3	32.4 ± 3.24	.023
Waist circumference, cm	107.1 ± 9.3	109.9 ± 9.5	107.4 ± 8.9	106.2 ± 9.3	105.2 ± 9.4	106.3 ± 9.2	<.001
General obesity[a], n (%)	1467(74)	275(81)	479(72)	500(71)	186(75)	27(71)	.013
Abdominal obesity[b], n (%)	1834(92)	307(91)	615(93)	650(93)	226(92)	36(95)	.621
Type 2 Diabetes, n (%)	668(36)	133(39)	238(36)	230(33)	69(28)	21(55)	.002
Hypertriglyceridemia, n (%)	838(42)	138(41)	264(40)	297(42)	119(48)	20(53)	.131
High blood pressure, n (%)	1860(93)	320(94)	613(93)	657(94)	234(95)	36(95)	.705
Hyperglycemia, n (%)	1367(69)	249(73)	462(69)	475(68)	154(62)	27(71)	.064
Low HDL-c, n (%)	907(46)	148(44)	307(46)	316(45)	118(48)	18(47)	.855
Sleep apnea, n (%)	251(13)	53(15)	77(12)	94(13)	24(10)	3(8)	.168
Depression, n (%)	420(21)	63(18)	115(17)	161(23)	69(28)	12(32)	.001
Fasting plasma glucose, mg/dl	113.7 ± 29.1	116.5 ± 31.7	113.7 ± 28.0	113.1 ± 28.8	110.0 ± 26.6	125.5 ± 38.0	.007
HbA1c, %	6.1±0.8	6.2±0.9	6.1±0.8	6.1±0.7	6.0±0.7	6.5±0.9	.005
Anti-diabetic medication, n (%)	479(24)	88(26)	160(24)	164(23)	50(20)	17(45)	.020
Sedative treatment, n (%)	475(24)	59(17)	121(18)	188(27)	93(37)	14(37)	<.001
Smoking, n (%)							
Never	857(43)	100(29)	276(42)	329(47)	129(52)	23(61)	<.001
Former	894(45)	186(55)	308(46)	303(43)	87(35)	10(26)	
Current	235(12)	53(16)	78(12)	68(10)	31(13)	5(13)	
Alcohol intake, g/day	11.4 ± 15.4	14.6 ± 16.8	12.1 ± 16.6	10.7 ± 14.1	7.9 ± 12.8	8.5 ± 12.5	<.001
Carbohydrate intake, g/day	249.0± 80.4	255.3 ± 81.4	249.7 ± 82.6	245.8 ± 75.9	250.3 ± 84.3	230.4 ± 84.3	.260
Fat intake, g/day	103.9 ± 31.7	108.3 ± 34.6	105.2 ± 31.2	102.6 ± 30.6	99.9 ± 31.6	92.8 ± 25.3	.002
Protein intake, g/day	97.8± 24.5	98.8 ± 25.6	99.0 ± 24.4	97.3 ± 24.3	96.1 ± 23.0	90.7 ± 28.1	.142
Sugar intake, g/day	7.3 ± 12.9	8.5 ± 13.8	6.7 ± 12.9	7.5 ± 12.7	7.3 ± 13.4	4.4 ± 8.7	.186
Adherence to energy-restricted MedDiet	8.6 ± 2.7	8.3 ± 2.7	8.7 ± 2.7	8.6 ± 2.7	8.7 ± 2.7	9.7 ± 2.9	.008

Table 2. Multivariable-adjusted β-coefficients (95%CI) per increment of 1h accelerometer-derived nocturnal sleep duration in relation to anthropometry and DXA-derived parameters, fasting plasma glucose and glycated hemoglobin.

parameters							
BMI, kg/m^2	1986	-0.37 (-0.52, -0.22)	<.001	.005	-0.38 (-0.54, -0.23)	<.001	.005
WC, cm	1986	-0.82 (-1.20, -0.43)	<.001	.005	-0.86 (-1.25, -0.47)	<.001	.005
Fasting plasma glucose, mg/dl	1986	-0.74 (-2.04, 0.55)	.262	.262	-0.60 (-1.92, 0.71)	.369	.369
HbA1c, %	1986	-0.04 (-0.07, -0.01)	.026	.057	-0.03 (-0.06, 0.001)	.056	.108
DXA-derived parameters							
Total fat, kg	649	-0.54 (-1.08, 0.09)	.054	.089	-0.49 (1.05, 0.05)	.077	.121
Android fat, kg	649	-0.10 (-0.17, -0.03)	.007	.025	-0.09 (-0.17, -0.02)	.009	.033
Gynoid fat, kg	649	-0.07 (-0.17, 0.02)	.140	.171	-0.06 (-0.16, 0.03)	.184	.224
Android-Gynoid ratio	649	-0.010 (-0.023, 0.003)	.118	.162	-0.011 (-0.024, 0.002)	.105	.144
VAT, kg	288	-0.08 (-0.17, 0.002)	.057	.089	-0.08 (-0.17, 0.003)	.059	.108
Trunk Fat Mass, kg	649	-0.43 (-0.77, -0.09)	.012	.033	-0.42 (-0.76, -0.08)	.016	.044
Lean Mass, kg	649	-0.25 (-0.65, 0.14)	.207	.227	-0.23 (-0.63, 0.16)	.252	.277

Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; DXA, dual-energy X-ray absorptiometry; WC, waist circumference. VAT, visceral adipose tissue.

Linear regression models for sleep duration and night-to-night sleep variability and the presented continuous outcomes. Model adjusted for sex, age (years), marital status (single/divorced, married and widower), employment (working, non-working, retired), education (primary education, secondary education, academic/graduate), smoking habit (current smoker, past smoker, never smoked), sedative treatment (yes/no), sleep apnea (yes/no), type 2 diabetes (yes/no), depression (yes/no), 17-score energy-restricted Mediterranean diet, alcohol intake (g/day, continuous and adding a quadratic term), compliance to MVPA recommendations set in ≥150 min/week (yes/no), time spent in sustained inactivity bouts ("daytime napping", min/day, log10 transformed) and intervention center. Model of fasting plasma glucose was additionally adjusted for waist circumference. Model for HbA1c was additionally adjusted for waist circumference and anti-diabetic treatment (yes/no).

P-value from linear regression for sleep duration and night-to-night sleep variability and the presented outcomes.

‡Adjusted *P*-value for multiple-testing using Benjamin-Hochberg procedure considering FDR <0.05 as significant.

[a] Model additionally adjusted for sleep variability (continuous).

Table 3. Multivariable-adjusted β-coefficients (95%CI) per increment of 1h accelerometer-derived night-to-night sleep variability in relation to anthropometry and DXA-derived parameters, fasting plasma glucose and glycated hemoglobin.

Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; DXA, dual-energy X-ray absorptiometry; WC, waist circumference; VAT, visceral adipose tissue.

Linear regression models for sleep duration and night-to-night sleep variability and the presented continuous outcomes. Model adjusted for sex, age (years), marital status (single/divorced, married and widower), employment (working, non-working, retired), education (primary education, secondary education, academic/graduate), smoking habit (current smoker, past smoker, never smoked), sedative treatment (yes/no), sleep apnea (yes/no), type 2 diabetes (yes/no), depression (yes/no), 17-score energy-restricted Mediterranean diet, alcohol intake (g/day, continuous and adding a quadratic term), compliance to MVPA recommendations set in ≥150 min/week (yes/no), time spent in sustained inactivity bouts ("daytime napping", min/day, log10 transformed) and intervention center. Model of fasting plasma glucose was additionally adjusted for waist circumference. Model for HbA1c was additionally adjusted for waist circumference and anti-diabetic treatment (yes/no).

Outcomes	**n**	**Sleep variability (h)**	***P*-value**	**Adjusted *P*-value[‡]**	**Sleep variability (h)[a]**	***P*-value**	**Adjusted *P*-value[‡]**
Anthropometry and glucose parameters							
BMI, kg/m^2	1986	0.01 (-0.36, 0.33)	.935	.935	-0.16 (-0.51, 0.19)	.377	.460
WC, cm	1986	-0.35 (-1.23, 0.54)	.440	.537	-0.67 (-1.56, 0.22)	.141	.387
Fasting plasma glucose, mg/dl	1986	2.11 (-0.84, 5.05)	.161	.431	1.88 (-1.11, 4.86)	.218	.434
HbA1c, %	1986	0.07 (0.02, 0.14)	.045	.355	0.06 (-0.01, 0.13)	.097	.387
DXA-derived parameters							
Total fat, kg	649	1.39 (-0.14, 2.93)	.075	.355	1.26 (-0.27, 2.80)	.107	.387
Android fat, kg	649	0.12 (-0.08, 0.32)	.246	.451	0.09 (-0.11, 0.30)	.359	.460
Gynoid fat, kg	649	0.23 (-0.04, 0.51)	.097	.355	0.22 (-0.06, 0.49)	.126	.387
Android-Gynoid ratio	649	-0.010 (-0.046, 0.027)	.606	.666	-0.012 (-0.049, 0.024)	.506	.506
VAT, kg	288	0.41 (-0.23, 0.40)	.287	.451	0.14 (-0.12, 0.39)	.299	.460
Trunk Fat Mass, kg	649	0.47 (-0.48, 1.43)	.328	.451	0.36 (-0.58, 1.32)	.452	.497
Lean Mass, kg	649	0.73 (-0.38, 1.85)	.196	.431	0.67 (-0.44, 1.79)	.237	.434

P-value from linear regression for sleep duration and night-to-night sleep variability and the presented outcomes.

[‡]Adjusted *P*-value for multiple-testing using Benjamin-Hochberg procedure considering FDR <0.05 as significant.

[a] Model additionally adjusted for sleep duration (continuous).

Table 4. Multivariable-adjusted β-coefficients (95%CI) for anthropometry and DXA-derived parameters, fasting plasma glucose, and glycated hemoglobin in bad sleepers [a] *vs*. good sleepers [b].

Outcomes	Good sleepers (n=400)	Bad sleepers (n=147)	*P*-value	Adjusted *P*-value[‡]
Anthropometry and glucose parameters				
BMI, kg/m^2	Ref.	0.87 (0.22, 1.51)	.008	.029
WC, cm	Ref.	1.47 (-0.18, 3.13)	.081	.222
Fasting plasma glucose, mg/dl	Ref.	7.89 (2.38, 13.40)	.005	.027
HbA1c, %	Ref.	0.37 (0.21, 0.52)	<.001	.011
DXA-derived parameters				
Total fat, kg	Ref.	1.36 (-0.94, 3.66)	.246	.338
Android fat, kg	Ref.	0.23 (-0.06, 0.54)	.130	.256
Gynoid fat, kg	Ref.	0.50 (-0.36, 0.46)	.813	.813
Android-Gynoid ratio	Ref.	0.04 (-0.01, 0.09)	.140	.256
VAT, kg	Ref.	0.17 (-0.19, 0.53)	.354	.432
Trunk fat mass, kg	Ref.	0.88 (-0.54, 2.31)	.222	.338
Lean mass, kg	Ref.	0.41 (-1.25, 2.07)	.625	.687

Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; DXA, dual-energy X-ray absorptiometry; WC, waist circumference; VAT, visceral adipose tissue; Ref., reference category. Linear regression models for "bad sleepers" *vs*. "good sleepers" (Ref.) and the presented continuous outcomes. Model adjusted for sex, age (years), marital status (single/divorced, married and widower), employment (working, non-working, retired), education (primary education, secondary education,

academic/graduate), smoking habit (current smoker, past smoker, never smoked), sedative treatment (yes/no), sleep apnea (yes/no), type 2 diabetes (yes/no), depression (yes/no), 17-score energy-restricted Mediterranean diet, alcohol intake (g/day, continuous and adding a quadratic term), compliance to MVPA recommendations set in ≥150 min/week (yes/no), time spent in sustained inactivity bouts ("daytime napping", min/day, log10 transformed) and intervention center.

P-value from linear regression for category of "bad sleepers" vs. "good sleepers" (Ref.) and the presented outcomes.

‡Adjusted *P*-value for multiple-testing using Benjamin-Hochberg procedure considering FDR <0.05 as significant.

[a]Bad sleepers: non-recommended sleep duration (<6h/night sleep for individuals with <65y and <5h/night for individuals with ≥65y or ≥9h/night) plus high sleep variability (≥ median sleep SD).

[b]Good sleepers: recommended sleep duration (7-9 h/night sleep for individuals with <65y and 7-8h/night for individuals with ≥65y) plus low sleep variability (< median sleep SD)